ATE241354T1 - Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis - Google Patents
Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosisInfo
- Publication number
- ATE241354T1 ATE241354T1 AT95937658T AT95937658T ATE241354T1 AT E241354 T1 ATE241354 T1 AT E241354T1 AT 95937658 T AT95937658 T AT 95937658T AT 95937658 T AT95937658 T AT 95937658T AT E241354 T1 ATE241354 T1 AT E241354T1
- Authority
- AT
- Austria
- Prior art keywords
- tetradecyloxy
- disease
- alzheimer
- furane
- psychosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/330,518 US5607967A (en) | 1994-10-27 | 1994-10-27 | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
PCT/US1995/013931 WO1996013257A1 (en) | 1994-10-27 | 1995-10-24 | Use of receptor potentiators |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE241354T1 true ATE241354T1 (de) | 2003-06-15 |
Family
ID=23290124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95937658T ATE241354T1 (de) | 1994-10-27 | 1995-10-24 | Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis |
Country Status (9)
Country | Link |
---|---|
US (1) | US5607967A (de) |
EP (1) | EP0786995B1 (de) |
JP (1) | JP3881011B2 (de) |
AT (1) | ATE241354T1 (de) |
AU (1) | AU705987B2 (de) |
CA (1) | CA2200886A1 (de) |
DE (1) | DE69530933T2 (de) |
ES (1) | ES2198447T3 (de) |
WO (1) | WO1996013257A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0726073A3 (de) * | 1995-02-10 | 1998-07-08 | Eduardo Samuel Bleiweiss | Pharmazeutische Zusammensetzungen, welche mindestens eine von Haloperidol, Imipramine oder Trifluorperazine enthalten |
EP1006794B1 (de) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
IL135659A0 (en) * | 1997-10-28 | 2001-05-20 | Schering Corp | Method of reducing craving in mammals |
US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
US6890716B1 (en) * | 1998-05-07 | 2005-05-10 | Howard Hughes Medical Institute | Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
US20030086923A1 (en) * | 1999-12-13 | 2003-05-08 | Sparrow Carl P. | Method for the prevention and/or treatment of atherosclerosis |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
ES2323940T3 (es) | 2000-05-01 | 2009-07-28 | Accera, Inc. | Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer. |
GB0017951D0 (en) * | 2000-07-22 | 2000-09-13 | Univ Manchester | Treatment of movement disorders |
US20040053265A1 (en) * | 2000-08-24 | 2004-03-18 | Rainer Hipfel | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders |
US6924311B2 (en) * | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
CA2469435A1 (en) * | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
US20030185884A1 (en) * | 2002-04-01 | 2003-10-02 | Singh Nikhilesh Nihala | Therapeutic agent delivery compositions for buccal cavity absorption of pilocarpine |
EP1572660B1 (de) * | 2002-12-20 | 2011-01-26 | X-Ceptor Therapeutics, Inc. | Isochinolinonderivate und deren verwendung als medikamente |
US20080213363A1 (en) * | 2003-01-23 | 2008-09-04 | Singh Nikhilesh N | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa |
WO2005101007A1 (en) * | 2004-04-15 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with liver x receptor beta (lxrb) |
EP2001293B9 (de) | 2006-04-03 | 2019-04-17 | Accera, Inc. | Verwendung ketogener verbindungen zur behandlung altersbedingter gedächtnisschwächen |
CA2685380A1 (en) * | 2007-05-14 | 2008-11-20 | Neuera Pharmaceuticals, Inc. | Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism |
PT2650378E (pt) | 2007-07-31 | 2016-01-14 | Accera Inc | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida |
JP4746714B2 (ja) * | 2008-05-16 | 2011-08-10 | Axis株式会社 | 線維筋痛症治療用医薬組成物 |
CN105640931A (zh) * | 2008-07-03 | 2016-06-08 | 艾克塞拉公司 | 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物 |
US11298361B2 (en) * | 2012-07-12 | 2022-04-12 | Emalex Biosciences, Inc. | Fused benzazepines for treatment of Tourette's Syndrome |
CN110833621A (zh) * | 2019-12-06 | 2020-02-25 | 中国医科大学 | 多巴胺受体1拮抗剂在制备治疗对氯胺酮致小鼠类精神分裂症药物上的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601247A1 (fr) * | 1986-07-09 | 1988-01-15 | Merk Sharp Dohme Chibret Labor | Combinaison d'agents beta-bloquants et de pilocarpine. |
US4981784A (en) * | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
US5153205A (en) * | 1990-10-01 | 1992-10-06 | Merck & Co., Inc. | Method to reduce introacular pressure without causing miosis |
AU682007B2 (en) * | 1992-07-24 | 1997-09-18 | Johns Hopkins University, The | Use of inhibitors of fatty acid synthesis for treating cancer |
-
1994
- 1994-10-27 US US08/330,518 patent/US5607967A/en not_active Expired - Fee Related
-
1995
- 1995-10-24 WO PCT/US1995/013931 patent/WO1996013257A1/en active IP Right Grant
- 1995-10-24 EP EP95937658A patent/EP0786995B1/de not_active Expired - Lifetime
- 1995-10-24 DE DE69530933T patent/DE69530933T2/de not_active Expired - Fee Related
- 1995-10-24 CA CA002200886A patent/CA2200886A1/en not_active Abandoned
- 1995-10-24 ES ES95937658T patent/ES2198447T3/es not_active Expired - Lifetime
- 1995-10-24 JP JP51476796A patent/JP3881011B2/ja not_active Expired - Fee Related
- 1995-10-24 AT AT95937658T patent/ATE241354T1/de not_active IP Right Cessation
- 1995-10-24 AU AU39700/95A patent/AU705987B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0786995B1 (de) | 2003-05-28 |
JP3881011B2 (ja) | 2007-02-14 |
EP0786995A1 (de) | 1997-08-06 |
AU3970095A (en) | 1996-05-23 |
ES2198447T3 (es) | 2004-02-01 |
WO1996013257A1 (en) | 1996-05-09 |
DE69530933T2 (de) | 2004-02-12 |
US5607967A (en) | 1997-03-04 |
CA2200886A1 (en) | 1996-05-09 |
EP0786995A4 (de) | 1997-08-20 |
DE69530933D1 (de) | 2003-07-03 |
JPH10509139A (ja) | 1998-09-08 |
AU705987B2 (en) | 1999-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE241354T1 (de) | Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis | |
DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
ATE411026T1 (de) | Mittel zur behandlung der alzheimer-krankheit | |
NL300140I2 (nl) | Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer. | |
ATE262895T1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
ATE231724T1 (de) | Kombinationstherapie für die behandlung von psychosen | |
DE68913667T2 (de) | Imidazole für die Behandlung von Atherosclerose. | |
DE69130497T2 (de) | Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis | |
SE9502921D0 (sv) | New compounds | |
ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE69007486D1 (de) | Verwendung von calciumantagonisten für die behandlung von narben. | |
DE69622889T2 (de) | Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten | |
ATE179594T1 (de) | Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie | |
ATE113591T1 (de) | 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva. | |
DE3751362D1 (de) | 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva. | |
ATE330604T1 (de) | Behandlung von manischen erkrankungen | |
DE69302799D1 (de) | Zusammensetzung für die Behandlung von Kesselwasser | |
DE689838T1 (de) | Verwendung von Diademosim 5',5'''-p1,p4-Tetraphosphat zur Behandlung von ischämischen Myokard-Erkrankungen | |
DE69627298D1 (de) | Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten | |
DE59101581D1 (de) | Verwendung von efeu zur topischen behandlung der psoriasis. | |
DE69917445D1 (de) | Reinigung von carboxaldehyd | |
FR2707166B1 (fr) | Utilisation de l'efaroxan et de ses dérivés pour la fabrication de médicaments destinés au traitement de maladies neurodégénératives et leur progression . | |
DE68926222D1 (de) | Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen | |
DE3684825D1 (de) | Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |